Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note

An adaptive clinical trials procedure for a sensitive subgroup examined in the multiple sclerosis context

(2016) Corinne A Riddell et al.   STATISTICAL METHODS IN MEDICAL RESEARCH

Modelling the natural history of primary progressive multiple sclerosis

(2014) Katharine E Harding et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Randomized study combining interferon and glatiramer acetate in multiple sclerosis

(2013) Fred D. Lublin et al.   ANNALS OF NEUROLOGY

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis

(2012) Giancarlo Comi et al.   NEW ENGLAND JOURNAL OF MEDICINE

The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics

(2012) J.W. Lindsey et al.   Multiple Sclerosis and Related Disorders

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

(2011) Paul O'Connor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Possible clinical outcome measures for clinical trials in patients with multiple sclerosis

(2010) Myla D. Goldman et al.   Therapeutic Advances in Neurological Disorders

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

(2009) Ludwig Kappos et al.   LANCET NEUROLOGY

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY